Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition

Dr.Reddy's Laboratories

Status and phase

Completed

Phase 1

Conditions

Fed

Treatments

Drug: Olanzapine OD Tablets 5 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT01503450

BE-171-OLAN-2006

Details and patient eligibility

About

The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.

Full description

An open label, balanced, randomized, two treatment, two-sequence, two-period, single-dose, crossover comparative bioequivalence study of Olanzapine 5 mg OD Tablets, of Dr. Reddy's Laboratories Limited and Zyprexa Zydis 5 mg Tablets of Cardinal Health in healthy, human subjects under fed conditions.

Enrollment

26 patients

Sex

All

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy human subjects within the age range of 18 to 45 years
Non-smokers since at least six months
Willingness to provide written informed consent to participate in the study
Body-mass index of ≥18.5 kg/m2 and ≤ 24.9 kg/m2, with body weight not less than 50 kg
Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluations, medical history or physical examination during the screening
Normal 12-lead ECG or one with abnormality considered to be clinically insignificant
Normal chest X-ray PA view
Comprehension of the nature and purpose of the study and compliance with the requirement of the protocol
Female Subjects
- of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams. Jellies, diaphragm, intrauterine device (IUD), or abstinence, or
- postmenopausal for at least 1 year, or
- surgically sterile (bilateral tubal ligation. bilateral oophorectomy, or hysterectomy has been performed on the subject

Exclusion criteria

Personal / family history of allergy or hypersensitivity to olanzapine or allied drugs
Past history of anaphylaxis or angioedema
Any major illness in the past three months or any clinically significant ongoing chronic medical illness e.g. congestive heart failure, hepatitis, pancreatitis etc.
Presence of any clinically significant abnormal values during screening e.g. significant abnormality of liver Function Test (LFT), Renal (kidney) Function Test (RFT), etc.
Any cardiac, renal or liver impairment, any other organ or system impairment
History of seizure or psychiatric disorders
Presence of disease markers of HIV 1 and 2, and hepatitis Band C virus
Consumption of alcohol for more than two years, or consumption of more than three alcoholic drinks per day or consumption of alcohol within 48 hours prior to dosing and during the study [one drink is equal to one unit of alcohol [ one glass Wine, half plnt boor, and one measure (one ounce) of spirit).
Consumption of xanthine containing derivatives (coffee, tea, cola drinks. chocolate) within 48 hours before check-in of each period
Use of any recreational drug or a history of drug addiction
Participation in any clinical trial within the past 3 months
Inaccessibility of veins in left and right arm
Donation of blood (one unit or 350 mL) within 3 months prior to receiving the first dose of study medication
Receipt of any prescription drug therapy within four weeks or over-the-counter (OTC) drugs within two weeks prior to receiving the first dose of study medication or repeated use of drugs Within the last four weeks
An unusual diet, for whatever reason e.g. low sodium diet, for two weeks prior to receiving any medication and through out subject's participation in the study
Consumption of grapefruit- containing food or beverages within 7 days prior to receiving the first dose of study medication in both the periods
Recent history of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to the study
Female volunteers demonstrating a positive pregnancy screen or currently breast-feeding
Having an occupation or requirement of driving a vehicle or operate a complex machinery before 21 days of taking the drug in both periods